Wnt signaling has recently been implicated in carcinogenesis. We studied the activity of Wnt signaling and the methylation status of WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 by methylation-specific PCR in myeloma cell lines and primary myeloma samples. Of the four cell lines, Wnt signaling was constitutively activated in LP1 and WL2, correlating with hypermethylation and hence silencing. Moreover, 5-aza-2 0 -deoxycytidine treatment of these two cell lines showed progressive demethylation of methylated Wnt inhibitors, reexpression of transcripts and downregulation of Wnt signaling. In both LP1 and WL2 cells, multiple Wnts and Fzs were simultaneously expressed. Treatment of WL2, in which SFRP1 was completely methylated, with recombinant secreted Frizzled-related protein 1 (SFRP1) induced downregulation of Wnt signaling and inhibition of proliferation. In primary myeloma samples, 42% patients had methylation of at least one of these seven genes, of which 61.9% had X2 genes methylated. In conclusion, Wnt signaling is constitutively activated in myeloma, associated with methylation silencing of one or multiple soluble Wnt antagonists. An autocrine loop regulating Wnt signaling was demonstrated in the myeloma plasma cells, in which cellular proliferation was efficiently inhibited by recombinant SFRP1. Methylation study of a panel of genes, regulating a cellular pathway instead of isolated genes, is important.
Introduction
The Wnt signaling pathway is important in embryogenesis, hematopoiesis and development. 1 Two Wnt pathways have been elucidated: the canonical and noncanonical pathways. Activation of the canonical pathway is mediated by b-catenin while activation of the noncanonical pathway is independent of b-catenin. In the absence of Wnt ligand, b-catenin, central to the canonical Wnt intracellular signaling, is phosphorylated by glycogen synthase kinase (GSK)-3b (GSK3b) in a cytoplasmic complex comprising adenomatous polyposis coli (APC), Axin and GSK3b, which leads to proteasomal degradation of b-catenin. 1 In contrast, binding of Wnt to Frizzled (Wnt receptor), in the presence of coreceptor, low-density lipoprotein receptorrelated proteins (LRP5/6), leads to activation of Dishevelled (a cytoplasmic effector) and thus inhibition of GSK3b, resulting in hypophosphorylation and thus stabilization of b-catenin. After being translocated to the nucleus, nonphosphorylated b-catenin will activate transcription of target genes via a complex with T-cell factor/lymphocyte-enhancing factor families of transcription factor (TCF/LEF).
The canonical Wnt signaling pathway, however, is negatively regulated by a multitude of soluble factors in the extracellular milieu. These include (1) Wnt inhibitory factor 1 (WIF1), 2 secreted Frizzled-related proteins (SFRPs) and (3) Dickkorf (Dkk) family of secreted proteins, which antagonize Wnt signaling by binding to LRP5/6 component (coreceptors for Frizzled) of the Wnt receptor complex.
2 WIF1 encodes a secreted protein with a unique and highly conserved WIF domain. 3 The SFRP family consists of five members in humans, each containing a cysteinerich domain (CRD) which shares 30-50% sequence homology with the CRD of Frizzled receptors. 4 Both WIF1 and SFRP bind to Wnt ligands and thus inhibit their activities. Besides, SFRPs may also downregulate Wnt signaling by the formation of inhibitory complex with Frizzled receptors. On the other hand, DKKs acts by forming a ternary complex with LRP5/6, resulting in endocytosis and hence depletion of LRP receptors from the surface, thereby resulting in failure of Frizzled activation even in the presence of Wnt ligands. 5 DNA methylation involves the addition of a methyl group to the carbon-5 position of the cytosine ring in the CpG dinucleotide, and converting it to methylcytosine. 6, 7 The process is catalyzed by DNA methyltransferase. In many cancers, the CpG islands of selected genes are aberrantly methylated (hypermethylated), resulting in transcriptional repression. This may serve as an alternative mechanism of gene inactivation. Multiple genes have been shown to be frequently methylated in cancers and leukemias. 6, 8 Deregulation of the Wnt signaling pathway has been implicated in a wide array of cancers, 9 ,10 mostly through a loss-of-function mutations of APC and Axin; or gain-of-function mutation of CTNNB1 (b-catenin). 9, 11, 12 Recent studies have shown that overexpression of b-catenin could lead to enhanced proliferation in myeloma plasma cells. 10 Therefore, soluble Wnt inhibitors are potential tumor suppressor genes, which, if inactivated, may contribute to myeloma pathogenesis. Here, we studied the role of aberrant gene methylation of a panel of soluble Wnt antagonists including WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 in the activation of the canonical Wnt signaling pathway in multiple myeloma (MM). SFRP3 was not studied because of the absence of a CpG island.
Materials and methods

Patient, diagnosis and treatment
Thirty male and 20 female patients with MM at a median age of 57 (25-87) years were studied. The diagnosis of MM was based on standard criteria. 13 Complete staging work-up included bone marrow examination, skeletal survey, serum and urine protein electrophoresis and serum immunoglobulin (IgG, IgA and IgM) levels. Monoclonal proteins were identified by electrophoresis, immunoelectrophoresis and immunofixation. There were seven (14%) Durie-Salmon stage I, 13 (26%) stage II and 30 (60%) stage III patients. Patients with stage I or asymptomatic disease did not receive chemotherapy until disease progression. Patients below 65 years of age were induced with three to six courses of vincristine, adriamycin and dexamethasone (VAD) for initial myeloma cytoreduction. The study has been approved by IRB of Queen Mary Hospital with informed consent.
Methylation-specific polymerase chain reaction (MSP)
DNA was extracted from 50 myeloma bone marrow samples at diagnosis and myeloma cell lines (WL2, LP1, RPMI8226 and ARH77) by standard method. MSP for aberrant gene promoter methylation was performed as previously described. 14, 15 Treatment of DNA with bisulphite for conversion of unmethylated cytosine to uracil (but unaffecting methylated cytosine) was performed with a commercially available kit (CpGenome DNA modification kit, Chemicon, New York, NY, USA). Methylation status of Wif1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 were tested. Primers for the methylated (M-MSP) and unmethylated (U-MSP) promoters are shown in Table 1 . DNA from eight normal bone marrow donors was used as negative control, while methylated control DNA (CpGenome Universal Methylated DNA, Chemicon) was used as positive control in all the experiments. MSP was performed in a thermal cycler (9700, ABI Biosystems, Foster City, CA, USA) with the following cycling conditions: 95 1C for 4 min, 35 cycles of 95 1C for 45 s, specific annealing temperature for 30 s, 72 1C for 30 s and a final extension of 10 min at 72 1C. The MSP mixture contained 50 ng of bisulfite-treated DNA, 0.2 mM dNTPs, 2 mM MgCl 2 , 10 pmol of each primer, 1 Â PCR buffer and 2.5 U of AmpliTaq Gold DNA Polymerase (ABI Biosystems) in a final volume of 50 ml. Ten microliters of PCR products was loaded onto 6% non-denaturing polyacrylamide gels, electrophoresed and visualized under ultraviolet light after staining with ethidium bromide. to the cells in each well and incubated at 37 1C in dark for 4 h, after which the culture medium was aspirated and 100 ml dissolving reagent (0.1 N HCl in anhydrous isopropanol) was added to each well and mixed thoroughly to dissolve the formazan crystals. Absorbance at 570 and 650 nM was measured on a Labsystem Multiscan Microplate Reader and growth, as a percentage of control, was determined from the formula: % of control growth ¼ A=BÂ100 where A is the absorbance of SFRP-treated cells and B is the absorbance of control cells (that is, BSA-treated cells). The assays were performed in triplicate, and the results represent the mean value7s.d. from four independent experiments. All plates were read within 30-60 min upon the addition of MTT solvent. Western Blot for total and nonphosphorylated b-catenin LP1, RPMI8226, ARH77 and WL2 were studied for the status of Wnt signaling by western blotting. Cells were lysed in RIPA buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride (PMSF), 25 mg ml À1 of leupeptin, 25 mg ml À1 of aprotinin, 25 mg ml À1 pepstatin and 100 mM sodium orthovanadate. After 30 min of incubation on ice, lysates were passed through a 25 G needle and cell debris was removed by centrifugation at 12 000 r.p.m. for 20 min at 4 1C. Protein concentration was determined using the Dc Protein Assay kit (Bio-Rad Laboratories, Hercules, CA, USA), and equal amounts of extracts were fractionated on a 10% SDS-polyacrylamide gel. Following electrophoresis, proteins were electrophoretically transferred to a nitrocellulose membrane (Bio-Rad Laboratories). The blotted membranes were blocked with 5% BSA (Sigma) in Tris-buffered saline containing 0.1% Tween 20 (TBS-T), followed by incubation at 4 1C overnight with monoclonal anti-dephospho b-catenin at 1:2000 (Alexis Biochemicals, San Diego, CA, USA), monoclonal anti-total b-catenin at 1:1000 (Zymed Laboratories Inc., San Francisco, CA, USA) or monoclonal anti-actin at 1:3000 (Sigma). After primary antibody incubation, membranes were washed with TBS-T for 10 min for three times and incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG antibody (Zymed Laboratories) in 5% nonfat 
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Statistical analysis
Association between gene hypermethylation and other clinical parameters (age, sex, Durie-Salmon stage, paraprotein subtypes) was studied by the w 2 test (for categorical variables) or Student's t-test (for continuous variables). Overall survival (OS) was measured from the date of diagnosis to the date of last follow-up or death. Survival was estimated by the Kaplan-Meier method and compared by the log-rank test. All P-values were two-sided.
Results
Western blot analysis of myeloma cell lines for total and nonphosphorylated b-catenin
In myeloma cell lines, high levels of nonphosphorylated b-catenin was detected in LP1 and WL2, but absent or at very low levels in ARH77 and RPMI8226, suggestive of constitutive activation of Wnt signaling in LP1 and WL2 but inactive Wnt signaling in ARH77 and RPMI8226. Expression of total b-catenin was also detected in all four cell lines, with relatively lower expression in ARH77 (Figure 1 Myeloma cell lines. The profile of methylation of APC, WIF1, DKK3 and SFRPs of myeloma cell lines is listed in Table 3 and Figures 2a-d. WL2 was homozygously methylated for DKK3, SFRP1 and SFRP2, hemizygously methylated for SFRP4, SFRP5 and WIF1 but completely unmethylated for APC. LP1 was completely methylated for APC, DKK3, SFRP2 and SFRP5, hemizygously methylated for WIF1 and SFRP1. In ARH-77, apart from complete methylation of SFRP1, all these seven genes were completely unmethylated.
Primary myeloma samples. There were 11 (22%) with WIF1 methylation, 8 (16%) with DKK3 methylation, 9 (18%) with APC, 7 (14%) with SFRP1, 7 (14%) with SFRP4 and 2 (4%) cytosine (C) residues that were methylated remained unchanged as CpG (underlined), and cytosine residues that were unmethylated were changed to thymidine (T) (underlined). U-MSP showed that the methylated control (M) was totally methylated, and all eight normal controls (N1-N8) were unmethylated. In the M-MSP, the methylated control was methylated, but all normal controls were unmethylated. For the cell lines, WIF1 was hemizygously methylated in WL2 and LP1 but unmethylated in RPMI8226 and ARH-77. For the primary myeloma marrow samples, WIF1 was methylated in S2 and S6-8. P, positive control; B, reagent blank; MW, molecular weight control. (b) Adenomatous polyposis coli (APC) methylation. Sequence analysis of the M-MSP product showed the expected changes after bisulfite treatment. Wild-type (WT) cytosine (C) residues that were methylated remained unchanged as CpG (underlined), and cytosine residues that were unmethylated were changed to thymidine (T) (underlined). U-MSP showed that the methylated control (M) was totally methylated, and all eight normal controls (N1-N8) were unmethylated. In the M-MSP, the methylated control was methylated, but all normal controls were unmethylated. For the cell lines, APC was completely methylated in LP1 but completely unmethylated in others. For the primary myeloma marrow samples, APC was methylated in S1 and S5-S6. P, positive control; B, reagent blank; MW, molecular weight control. (c) Secreted Frizzled-related protein 2 (SFRP2) methylation. Sequence analysis of the M-MSP product showed the expected changes after bisulfite treatment. Wild-type (WT) cytosine (C) residues that were methylated remained unchanged as CpG (underlined), and cytosine residues that were unmethylated were changed to thymidine (T) (underlined). U-MSP showed that the methylated control (M) was totally methylated, and all eight normal controls (N1-N8) were unmethylated. In the M-MSP, the methylated control was methylated, but all normal controls were unmethylated. For the cell lines, SFRP2 was completely methylated in WL2 and LP1 but unmethylated in RPMI8226 and ARH-77. For the primary myeloma marrow samples, SFRP2 was methylated in S1, S4 and S7. P, positive control; B, reagent blank; MW, molecular weight control. (d) SFRP5 methylation. Sequence analysis of the M-MSP product showed the expected changes after bisulfite treatment. Wild-type (WT) cytosine (C) residues that were methylated remained unchanged as CpG (underlined), and cytosine residues that were unmethylated were changed to thymidine (T) (underlined). U-MSP showed that the methylated control (M) was totally methylated, and all eight normal controls (N1-N8) were unmethylated. In the M-MSP, the methylated control was methylated, but all normal controls were unmethylated. For the cell lines, SFRP5 was hemizygously methylated in WL2, completely methylated in LP1 but unmethylated in RPMI8226 and ARH-77. For the primary myeloma marrow samples, SFRP5 was methylated in S3. P, positive control; B, reagent blank; MW, molecular weight control.
with SFRP5 methylation. Moreover, 21 (42%) had methylation of at least one of these seven negative regulators of Wnt signaling genes. Of these 21 patients, there were 8 (38.1%) with methylation of one and 13 (61.9%) with methylation of two or more Wnt inhibitors (6 with methylation of two, 5 with methylation of three and 1 each with methylation of four and five genes).
5-AzadC treatment of LP1 and WL2 cell lines. LP1 was completely methylated for APC, DKK3, SFRP2 and SFRP5, with the absence of the corresponding transcripts on day 0. Upon 5-azadC demethylation treatment, MSP for APC, SFRP2
and SFRP5 showed U-MSP signals on day 4, with reemergence of the corresponding transcripts as shown by RT-PCR. Moreover, high levels of nonphosphorylated b-catenin protein were detected on day 0, which was markedly reduced on day 4 after 5-azadC demethylation treatment of LP1 (Figure 3a) . In WL2, DKK3, SFRP1 and SFRP2 were completely methylated, and thus not expressed on day 0. 5-AzadC treatment of WL2 resulted in partial demethylation of SFRP1 and SFRP2 (as evidenced by positive U-MSP amplification) and gene expression by RT-PCR on day 4 (Figure 3b) . Table 2b summarizes the results, and Figure 4 depicts some of the amplified Wnt and Fz isoform products. Of the eight Wnt isoforms tested, expression of Wnt3, Wnt4, Wnt7a, Wnt10a
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and Wnt14 was detected in both myeloma cell lines, whereas both cell lines were devoid of Wnt6 expression. Wnt8A was only detected in WL2 cells, and wnt11 was only expressed in LP1. LP1 cells were found to express all of the six analyzed Fz isoforms, and WL2 cells expressed all except for Fz4. GAPDH was used as an internal control for the experiments. 
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Effect of SFRP1 treatment on WL2 cells
Although Wnt and Fz were expressed in both myeloma cell lines, they could be dispensable for cell growth and survival. To test this possibility, the effects of recombinant SFRP1, a Wnt antagonist silenced by methylation in WL2 cells, were examined. Treatment with SFRP1 decreased WL2 cell proliferation (Figure 5a) . Moreover, the inhibition of cell growth was dependent on both the concentration of SFRP1 added and the duration of rhSFRP treatment, with greater decrease in cell viability observed with higher concentrations of SFRP1 and longer time of SFRP1 incubation. Next, the ability of exogenous SFRP1 to affect Wnt/b-catenin signaling in WL2 cells was examined. Treatment with 20, 60, 80 or 120 ng ml À1 SFRP1, but not the control, resulted in dose-dependent downregulation of Wnt/b-catenin signaling, as evidenced by a decrease in nonphosphorylated b-catenin expression (Figure 5b ).
Statistical Analysis
Of the 21 patients with methylation of at least one of these seven regulators of Wnt signaling, gene promoter methylation was not associated with age (mean age for those with and without methylation of any one of these genes were 58.5. and 54.9 years, P ¼ 0.22), sex (methylation of at least one gene occurred in 12 (40%) male and nine (45%) female patients (P ¼ 0.77), Durie-Salmon stage (methylation of at least one gene occurred in three (42.8%) stage I, five (38.5%) stage II and 13 (43.3%) stage III patients. (P ¼ 0.96) and paraprotein subtypes five (45.5%) with IgA, 14 (46.6%) IgG and two (28.6%) with light chain myeloma had methylation of at least one of these seven genes (P ¼ 0.41). However, the median OS for those with or without methylation of any one of these seven genes were 45 months and 46 months, (P ¼ 0.37).
Discussion
Of the four myeloma cell lines, constitutive activation of the Wnt signaling pathway was found in WL2 and LP1. This was demonstrated by the high levels of nonphosphorylated bcatenin, the active form that is able to translocate to the nucleus and activates TCF-dependent gene transcription. Moreover, the level of Wnt activation, correlating with the level of nonphosphorylated b-catenin, was comparable to the positive control SW480, a cell line with constitutive Wnt activation due to truncating APC mutation at codon 1338 and complete loss of the second allele.
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To elucidate the possible role of aberrant gene promoter methylation in constitutive activation of Wnt signaling in MM, the methylation status of promoter CpG islands of seven soluble Wnt antagonists including WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5, which negatively regulates canonical Wnt signaling, was studied by MSP in myeloma cell lines and diagnostic marrow samples from patients with MM. Indeed, we found that concurrent methylation of multiple genes regulating this pathway was associated with constitutive Wnt activation in two of the four studied cell lines (LP1 and WL2). Conversely, almost completely unmethylated status of the seven genes was observed in the two cell lines (ARH77 and OPMI8226) without Wnt activation. In addition, complete methylation led to silencing of the respective genes as evidenced by the absence of transcripts, whereas absence of gene methylation was associated with constitutive gene expression. Furthermore, in the two cell lines (LP1 and WL2) with constitutive activation of Wnt signaling, 5-azadC treatment of these cell lines resulted in progressive demethylation of methylated genes, re-expression of transcripts, and more importantly, downregulation of Wnt signaling as evidenced by downregulation of nonphosphorylated b-catenin. Therefore, aberrant promoter methylation of soluble Wnt inhibitors resulted in gene silencing, and may account for the constitutive activation of Wnt signaling in MM, which has been shown to be important in the pathogenesis of MM by enhancing cellular proliferation. 10 Our findings thus implicated soluble Wnt inhibitors as tumor suppressors that could be inactivated by methylation. This is in contrast to the recent findings that some soluble inhibitors including DKK1 and SFRP2 were overexpressed by myeloma plasma cells.
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The expression profile of Wnt family and Overexpression of these Wnt inhibitors resulted in inhibition of osteoblastic differentiation. In primary myeloma samples, about 40% of patients actually had methylation of at least one of these seven genes, illustrating the frequent methylation of these soluble Wnt antagonists in MM. Interestingly, of the 21 patients with methylation of at least one of these genes, 13 (61.9%) had methylation of 2 or more genes. This is an interesting phenomenon, as concurrent methylation of multiple genes regulating the same cellular pathway appears redundant. In cancer cells, activation of oncogenes or inactivation of tumor suppressor genes in a certain pathway is usually mutually exclusive. This is best illustrated by the study of cell cycle dysregulation in lung cancer. In small cell lung cancer, there is frequent inactivation of Rb but not CDKN2A. 24 Conversely, in nonsmall cell lung cancer, there is frequent CDKN2A but not Rb inactivation. 25 Therefore, concurrent methylation of multiple genes of the same cellular pathway remained to be explained. However, similar methylation of multiple soluble Wnt inhibitors of the SFRP family has been demonstrated in colon cancer. 26 Interestingly, in colon cancer cell lines with constitutive Wnt activation (due to mutations in CTNNB1 or APC), additional Wnt activation could be achieved by simultaneous methylation-associated silencing of multiple members of the SFRP family, or additional expression of b-catenin. 26 Therefore, the Wnt signaling axis in cells with constitutive activation of Wnt pathway is intact, and further up-or downregulation remains feasible. Similarly, while the Wnt pathway has been shown to be activated in myeloma cell lines, 10 the pathway remains intact and responsive to additional stimulation. For instance, treating myeloma cell lines (with constitutive Wnt activation) with Wnt agonist (LiCL) or Wnt ligands led to further increase in nonphosphorylated b-catenin levels, consistent with further activation of the Wnt pathway. Importantly, additional activation of the Wnt pathway actually translated into enhanced cellular proliferation. 10 Therefore, our finding of concurrent methylation of multiple Wnt inhibitors in both myeloma cell lines and primary samples suggested that maximal Wnt activation might be achieved in myeloma plasma cells by concomitant hypermethylation of multiple Wnt inhibitors.
This study also underscored the importance of studying gene hypermethylation of multiple genes regulating a particular cellular pathway. For instance, methylation occurred in only 4-22% primary myeloma samples had we chosen to study methylation of individual genes. However, twenty-one (42%) patients actually had methylation of at least one of these seven negative regulators when the methylation status of this panel of genes was studied simultaneously. Moreover, while mutation of b-catenin or APC has not been studied, it was shown to be absent in myeloma cell lines and primary myeloma samples. 10 Moreover, as aberrant gene promoter, methylation of E-CAD, SHP1 and CDKN2A has been demonstrated to be associated with disease progression in MM. 27 Therefore, the role of methylation of soluble Wnt inhibitors in disease progression warrants further study in MM.
In summary, we demonstrated the constitutive activation of Wnt signaling in myeloma cell lines that was associated with complete methylation and hence silencing of multiple Wnt inhibitors; and methylation of at least one of the seven soluble Wnt inhibitors was frequently observed in primary myeloma marrow samples. Furthermore, the presence of an autocrine loop regulating Wnt signaling by Wnt and Fz was also demonstrated in myeloma cells. These findings implicate a critical role of gene hypermethylation of soluble Wnt inhibitors in Wnt activation in MM, and underscore the importance of studying a panel of genes regulating a particular cellular pathway.
